Sernova Biotherapeutics Appoints Pericles Calias, Ph.D. as Chief Development Officer and Head of R&D
Sernova Biotherapeutics (OTCQB: SEOVF) has appointed Dr. Pericles (Perry) Calias as Chief Development Officer and Head of R&D. Dr. Calias brings over 20 years of global operational experience in drug product development, having previously held leadership positions at Revolo Biotherapeutics, Cerecor Inc., Sucampo Pharmaceuticals, and Shire HGT.
Dr. Calias will contribute to advancing Sernova's Cell Pouch Bio-hybrid Organ, which is being developed as a functional cure for type 1 diabetes (T1D). His expertise includes securing regulatory approvals, leading R&D efforts, patent applications, clinical operations, and advancing therapies in rare diseases, autoimmune disorders, CNS disorders, and drug-device combinations.
He holds a Ph.D. in Bio-Organic Chemistry from Tufts University and is an inventor on over 40 domestic and foreign patents. His experience includes successful regulatory filings of INDs, CTAs, PMAs, BLAs, and NDAs.
Sernova Biotherapeutics (OTCQB: SEOVF) ha nominato Dr. Pericles (Perry) Calias come Chief Development Officer e Responsabile della Ricerca e Sviluppo. Il Dr. Calias porta con sé oltre 20 anni di esperienza operativa globale nello sviluppo di prodotti farmaceutici, avendo ricoperto in precedenza ruoli di leadership presso Revolo Biotherapeutics, Cerecor Inc., Sucampo Pharmaceuticals e Shire HGT.
Il Dr. Calias contribuirà all'avanzamento del Cell Pouch Bio-hybrid Organ di Sernova, che è in fase di sviluppo come cura funzionale per il diabete di tipo 1 (T1D). La sua esperienza include l'ottenimento di approvazioni regolatorie, la guida degli sforzi di R&S, le domande di brevetto, le operazioni cliniche e l'avanzamento di terapie in malattie rare, disturbi autoimmuni, disturbi del sistema nervoso centrale e combinazioni farmaco-dispositivo.
Possiede un dottorato in Chimica Bio-Organica presso l'Università di Tufts ed è inventore di oltre 40 brevetti nazionali e stranieri. La sua esperienza include il successo nelle presentazioni regolatorie di IND, CTA, PMA, BLA e NDA.
Sernova Biotherapeutics (OTCQB: SEOVF) ha nombrado al Dr. Pericles (Perry) Calias como Director de Desarrollo y Jefe de I+D. El Dr. Calias aporta más de 20 años de experiencia operativa global en el desarrollo de productos farmacéuticos, habiendo ocupado anteriormente puestos de liderazgo en Revolo Biotherapeutics, Cerecor Inc., Sucampo Pharmaceuticals y Shire HGT.
El Dr. Calias contribuirá al avance del Cell Pouch Bio-hybrid Organ de Sernova, que se está desarrollando como una cura funcional para la diabetes tipo 1 (T1D). Su experiencia incluye la obtención de aprobaciones regulatorias, la dirección de esfuerzos de I+D, solicitudes de patentes, operaciones clínicas y el avance de terapias en enfermedades raras, trastornos autoinmunes, trastornos del sistema nervioso central y combinaciones de fármacos-dispositivos.
Tiene un doctorado en Química Bio-Orgánica de la Universidad de Tufts y es inventor de más de 40 patentes nacionales y extranjeras. Su experiencia incluye presentaciones regulatorias exitosas de IND, CTA, PMA, BLA y NDA.
서노바 바이오테라퓨틱스 (OTCQB: SEOVF)는 페리클레스 (페리) 칼리아스 박사를 최고 개발 책임자이자 연구개발 책임자로 임명했습니다. 칼리아스 박사는 약물 제품 개발 분야에서 20년 이상의 글로벌 운영 경험을 보유하고 있으며, 이전에 레볼로 바이오테라퓨틱스, 세레코르 주식회사, 수캄포 제약 및 샤이어 HGT에서 리더십 직책을 역임했습니다.
칼리아스 박사는 서노바의 셀 파우치 바이오 하이브리드 장기의 발전에 기여할 예정이며, 이는 제1형 당뇨병(T1D)의 기능적 치료제로 개발되고 있습니다. 그의 전문 분야에는 규제 승인 확보, 연구개발 노력 주도, 특허 출원, 임상 운영 및 희귀 질환, 자가면역 질환, CNS 질환 및 약물-기기 조합의 치료 발전이 포함됩니다.
그는 터프츠 대학교에서 생물유기화학 박사 학위를 보유하고 있으며, 40건 이상의 국내외 특허의 발명자입니다. 그의 경험에는 IND, CTA, PMA, BLA 및 NDA의 성공적인 규제 제출이 포함됩니다.
Sernova Biotherapeutics (OTCQB: SEOVF) a nommé Dr. Pericles (Perry) Calias au poste de Directeur du Développement et Responsable de la R&D. Le Dr. Calias apporte plus de 20 ans d'expérience opérationnelle mondiale dans le développement de produits pharmaceutiques, ayant précédemment occupé des postes de direction chez Revolo Biotherapeutics, Cerecor Inc., Sucampo Pharmaceuticals et Shire HGT.
Le Dr. Calias contribuera à l'avancement de l'organe bio-hybride Cell Pouch de Sernova, qui est en cours de développement comme un traitement fonctionnel pour le diabète de type 1 (T1D). Son expertise comprend l'obtention d'approvals réglementaires, la direction des efforts de R&D, les demandes de brevet, les opérations cliniques et l'avancement des thérapies dans les maladies rares, les troubles auto-immuns, les troubles du système nerveux central et les combinaisons de médicaments-dispositifs.
Il est titulaire d'un doctorat en chimie bio-organique de l'Université de Tufts et est inventeur de plus de 40 brevets nationaux et étrangers. Son expérience comprend des dépôts réglementaires réussis d'IND, CTA, PMA, BLA et NDA.
Sernova Biotherapeutics (OTCQB: SEOVF) hat Dr. Pericles (Perry) Calias zum Chief Development Officer und Leiter der Forschung und Entwicklung ernannt. Dr. Calias bringt über 20 Jahre globale Betriebserfahrung in der Arzneimittelentwicklung mit und hatte zuvor Führungspositionen bei Revolo Biotherapeutics, Cerecor Inc., Sucampo Pharmaceuticals und Shire HGT inne.
Dr. Calias wird dazu beitragen, das Cell Pouch Bio-hybrid Organ von Sernova voranzubringen, das als funktionale Heilung für Typ-1-Diabetes (T1D) entwickelt wird. Zu seinen Fachgebieten gehören die Sicherstellung von regulatorischen Genehmigungen, die Leitung von F&E-Bemühungen, Patentanmeldungen, klinische Operationen und die Entwicklung von Therapien bei seltenen Krankheiten, Autoimmunerkrankungen, Erkrankungen des zentralen Nervensystems und Arzneimittel-Geräte-Kombinationen.
Er hat einen Doktortitel in Bio-organischer Chemie von der Tufts University und ist Erfinder von über 40 nationalen und internationalen Patenten. Zu seinen Erfahrungen gehören erfolgreiche regulatorische Einreichungen von INDs, CTAs, PMAs, BLAs und NDAs.
- Appointment of experienced CDO with 20+ years in drug development
- Strong regulatory expertise with multiple successful drug approvals
- Extensive patent portfolio (40+ patents) demonstrating innovation track record
- Strategic collaboration with Evotec for T1D treatment development
- None.
Dr. Calias to add Operational Depth and Cell Therapy Expertise to Sernova
LONDON, Ontario and BOSTON, March 10, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics, (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a leading regenerative medicine company focused on developing it’s Cell Pouch Bio-hybrid Organ as a functional cure for type 1 diabetes (T1D), today announced the appointment of Pericles (Perry) Calias, Ph.D., as Chief Development Officer (CDO) and Head of R&D.
Dr. Calias brings over two decades of global operational experience in drug product development from discovery to approval. Prior to joining Sernova, he held leadership roles at prominent life sciences companies, including Revolo Biotherapeutics, Cerecor Inc., Sucampo Pharmaceuticals, and Shire HGT. Throughout his career, Dr. Calias has been instrumental in securing regulatory approvals, leading research and development efforts, filing many patent applications that were subsequently issued, spearheading clinical operations and advancing innovative therapies in rare diseases, autoimmune disorders, central nervous system (CNS) disorders and drug-device combinations.
“I have worked with Perry in the past and he brings a wealth of cross functional experience to the Sernova leadership team,” said Jonathan Rigby, President and CEO of Sernova Biotherapeutics. “His deep expertise in leading all aspects of drug product and cell line development is invaluable to Sernova and will add momentum to advancing our Cell Pouch Bio-hybrid Organ as a much-needed functional cure for T1D in collaboration with Evotec.”
"I am enthused to join Sernova as the company works to transform the treatment paradigm for T1D," said Dr. Calias. "The Cell Pouch Bio-hybrid Organ holds immense potential to provide a much-needed functional cure for patients that deal with the daily burdens and longer-term comorbidities."
Dr. Calias holds a Ph.D. in Bio-Organic Chemistry from Tufts University and a Bachelor of Science in Biology from Suffolk University. He is an inventor on over 40 domestic and foreign patents and has led multiple successful regulatory filings, including INDs, CTA’s, PMA’s, BLAs, and NDAs.
ABOUT SERNOVA BIOTHERAPEUTICS
Sernova Biotherapeutics is a clinical-stage company developing regenerative medicine therapeutics combining its Cell Pouch with human donor cells or stem-cell derived islet like clusters in collaboration with Evotec to create bio-hybrid organs to treat T1D. A bio-hybrid organ is comprised of non-biomaterials, such as the Cell Pouch, integrated with living tissues to restore or enhance the function of a compromised organ. This innovative approach aims to deliver a potentially revolutionary treatment for patients with chronic diseases, initially focusing on T1D and thyroid disorders.
FOR FURTHER INFORMATION, PLEASE CONTACT:
David Burke VP, Investor Relations (917) 751-5713 Email: David.Burke@sernova.com Website: https://sernova.com/
The TSX has not reviewed this news release and does not accept responsibility for the accuracy or adequacy of this news release.
FORWARD-LOOKING INFORMATION
This press release contains forward-looking statements within the meaning of applicable Canadian securities laws. Forward-looking statements in this press release include our expectation that Dr. Calias will greatly assist in Sernova’s development efforts. With respect to the forward-looking statements contained in this press release, Sernova has made numerous assumptions regarding, among other things: the company’s ability to secure additional financing on reasonable terms, or at all; and the ability to conduct all required preclinical and clinical studies for the company’s Cell Pouch, including the timing and results of those trials. A more complete discussion of the risks and uncertainties facing Sernova appears in Sernova’s Annual Information Form for the year ended October 31, 2024, filed with Canadian securities authorities and available at www.sedarplus.ca, as updated by Sernova’s continuous disclosure filings, which are available at www.sedarplus.ca. All forward-looking statements herein are qualified in their entirety by this cautionary statement, and Sernova disclaims any obligation to revise or update any such forward-looking statements or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, except as required by law.
FAQ
What is the significance of Dr. Calias joining Sernova Biotherapeutics (SEOVF) in March 2025?
How many patents is Dr. Calias credited with at Sernova Biotherapeutics (SEOVF)?
What is the main product focus for Sernova Biotherapeutics (SEOVF) under Dr. Calias?
What regulatory experience does Dr. Calias bring to Sernova (SEOVF)?
